Product Overview
[Drug Name]
Generic Name: H Irbesartan Dispersible Tablets
Trade Name: Haojiangzhi H Irbesartan Dispersible Tablets 0.15g*24s
Pinyin Code: HaoJiangZhi HEBeiShaTanFenSanPian 0.15g*24s
[Main Ingredient]
The main ingredient of this product is irbesartan. Chemical Name: 2-Butyl-3-[4-[2-(1H-tetrazol-5-yl)phenyl]benzyl]-1,3-diazaspiro-[4,4]non-1-en-4-one. Molecular Formula: C25H28N6O
Molecular Weight: 428.54
[Properties]
This product is a white or off-white tablet.
[Indications/Main Functions]
Treatment of essential hypertension. Treatment of type 2 diabetic nephropathy with hypertension.
[Specifications]
0.15g*24s
[Dosage and Administration]
The recommended initial and maintenance dose is 150mg daily. Dietary considerations have no impact on medication administration. Generally, 150mg of irbesartan once daily provides better 24-hour blood pressure control than 75mg. However, for certain patients, particularly those undergoing hemodialysis and those over 75 years of age, a 75mg initial dose may be considered. For patients whose blood pressure is not effectively controlled with 150mg of irbesartan once daily, the dose can be increased to 300mg or other antihypertensive medications can be added. In particular, the addition of diuretics such as hydrochlorothiazide has been shown to have an additive effect. For hypertensive patients with type 2 diabetes, the initial treatment dose should be 150mg once daily, increasing to 300mg once daily as a maintenance dose for kidney disease. Clinical studies have demonstrated that irbesartan has renal benefits in hypertensive patients with type 2 diabetes. In studies, irbesartan was used in combination with other antihypertensive medications, as needed, to lower blood pressure to target values. Renal Impairment: No dose adjustment is required for patients with renal impairment. However, a lower initial dose (75 mg) may be considered for patients undergoing hemodialysis. Volume Depletion: Patients with volume and/or sodium depletion should correct this before using this product. Hepatic Impairment: No dose adjustment is required for patients with mild to moderate hepatic impairment. There is currently no clinical experience with patients with severe hepatic impairment. Elderly Patients: Although a starting dose of 75 mg may be considered for patients over 75 years of age, dose adjustment is generally not required for elderly patients. Pediatric Population: The safety and efficacy of irbesartan in children aged 0-18 years have not been established, and no dose recommendation can be made based on available data.
[Adverse Reactions]
See package insert for details.
[Contraindications]
Known hypersensitivity to any of the ingredients in this product. Pregnancy (4th to 9th month). Lactation. Patients with diabetes or moderate to severe renal impairment (GFR less than 60 ml/min/1.73 m²) should not use this product in combination with aliskiren. Patients with diabetic nephropathy should not use this product in combination with angiotensin-converting enzyme (ACE) inhibitors.
[Precautions]
See package insert for details.
